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Abstract 
Background: Oleanolic acid, which can be isolated from many foods and medicinal plants, has been reported to 
possess diverse biological activities. It has been found that the acylation of the hydroxyl groups of the A‑ring in the 
triterpene skeleton of oleanolic acid could be favorable for biological activities. The pyrimidinyl group has been con‑
structed in many new compounds in various anti‑tumor studies.
Results: Five acyl oleanolic acid‑uracil conjugates were synthesized. Most of the IC50 values of these conjugates were 
lower than 10.0 μM, and some of them were even under 0.1 μM. Cytotoxicity selectivity detection revealed that con‑
jugate 4c exhibited low cytotoxicity towards the normal human liver cell line HL‑7702. Further studies revealed that 
4c clearly possessed apoptosis inducing effects, could arrest the Hep‑G2 cell line in the G1 phase, induce late‑stage 
apoptosis, and activate effector caspase‑3/9 to trigger apoptosis.
Conclusions: Conjugates of five different acyl OA derivatives with uracil were synthesized and identified as possess‑
ing high selectivity toward tumor cell lines. These conjugates could induce apoptosis in Hep‑G2 cells by triggering 
caspase‑3/9 activity.
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Background
Pentacyclic triterpenes, which are ubiquitous in the plant 
kingdom, have important ecological and agronomic func-
tions, and contribute greatly to pest and disease resist-
ance and to food quality in crop plants [1]. They are also 
applied in a variety of commercial uses in the food, cos-
metic and pharmaceutical fields. For example, pentacy-
clic triterpene imberbic acid, isolated from Combretum 
imberbe (Engl. and Diels), has been found to have par-
ticularly potent activity against Mycobacterium fortui-
tum and Staphylococcus aureus [2]. Other pentacyclic 
triterpenes have been reported to possess antioxidant, 
antiproliferative, and pro-apoptotic capacities on MCF-7 
human breast cancer cells [3]. They were also reported as 
a new class of glycogen phosphorylase inhibitors [4] and 
further proved to be multi-target therapeutic agents for 
the prevention and treatment of metabolic and vascular 
diseases [5]. Oleanolic acid (3β-hydroxyolean-12-en-28-
oic acid, OA, 1, Fig.  1), which belongs to the family of 
oleanane pentacyclic triterpenes, has been isolated from 
more than 1620 plant species, including many food and 
medicinal plants [6]. It is among the major effective com-
ponents of some well-known traditional chinese medi-
cines (TCM) such as Rehmannia Six Formula (Liu Wei Di 
Huang Wan), which is one of the most commonly used 
Chinese herb formulas in the world. It has been used as a 
nonprescription antihepatitis drug for almost 35 years in 
China [7]. Oleanolic acid and its derivatives have recently 
attracted much attention due to their diverse biological 
activities [8]. For instance, oleanolic acid and its deriva-
tives were reported to be inhibitors of protein tyrosine 
phosphatase 1B with cellular activities [9] and osteoclast 
formation [10, 11]. These compounds were also focused 
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on cytotoxicity evaluation [12]. Furthermore, some syn-
thetic oleanane triterpenoids (CDDO, CDDO-Me and 
CDDO-Im) have demonstrated potent antiangiogenic 
and antitumor activities in rodent cancer models [13, 14]. 
Other biological activities of oleanolic acid and its deriva-
tives, including antiproliferative activity in solid tumor 
cells [15], inhibition of α-glucosidase [16], and others [6, 
8], were also revealed.
The importance of C-3 in the oleanolic acid skeleton 
was elucidated (Fig.  1). The SAR analysis of oleanolic 
acid derivatives modified at C-3 and C-28 indicated that 
hydrogen-bond acceptor substitution at the C-3 position 
of oleanolic acid may be advantageous for the improve-
ment of cytotoxicity against PC-3, A549 and MCF-7 cell 
lines [12]. Gnoatto found that the derivative with an acet-
ylation at C-3 of the oleanolic acid backbone had much 
better activity against the L. amazonensis strain [17]. 
3-Oxo oleanolic acid (3-oxo-olea-12-en-28-oic acid), a 
derivative of oleanolic acid modified at C-3, was found 
to significantly inhibit the growth of cancer cells derived 
from different tissues, particularly on melanoma in vivo 
[18]. Some other acyl compounds, generated from the 
modification of the hydroxyl groups of the A-ring in the 
triterpene skeleton of oleanolic acid and maslinic acid 
(MA, Fig.  1) with 10 different acyl groups, displayed 
cytotoxic effects against b16f10 murine melanoma cells 
and showed apoptotic effects with high levels of early and 
total apoptosis (up to 90%). These acyl compounds also 
exhibited better inhibition effects to anti-HIV-1-protease, 
with IC50 values between 0.31 and 15.6  μM, which are 
4–186 times lower than their non-acylated precursors 
[19]. Compound 2 (Fig.  1), un benzyl (2α,3β) 2,3-diace-
toxy-olean-12-en-28-amide, exhibited much better cyto-
toxicity against human tumor cell lines compared with its 
deacylation product, while it showed a rather low cyto-
toxicity for human fibroblasts (WW030272) [20].
On the other hand, pyrimidine has been widely used 
as an anti-tumor pharmacophore in medicinal chemi-
cal research [21]. For instance, some new pyridines and 
pyrazolo [1,5-α] pyrimidines exhibited potent anti-tumor 
cytotoxic activity in  vitro against different human cell 
lines [22]. The evaluation of several ring-A fused hybrids 
of oleanolic acid against seven human cancer cell lines 
showed that the fused pyrimidine moiety seemed impor-
tant to enhance the antiproliferative activity of oleanolic 
acid [23]. Thus, the pyrimidinyl group has been con-




Inspired by the cited evidence, in this study, we conju-
gated five different acyl OA derivatives (3a–3e) [15, 19, 
20, 25, 26] with uracil. The synthetic routes are outlined 
in Schemes  1 and 2. The treatment of 1 (1 equiv) with 
anhydride (1.5 equiv) and DMAP (0.1 equiv) in anhydrous 
CH2Cl2/pyridine (1/7 = v/v) at room temperature afforded 
3-O-acyl derivatives 3a–3c [15, 19, 20, 25] (64–89%). The 
Fig. 1 Chemical structures of oleanane triterpene skeleton, oleanolic acid, maslinic acid and 2
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treatment of 1 (1 equiv) with acyl chloride (3 equiv) and 
Et3N (3.5 equiv) in anhydrous THF at room temperature 
gave acyl derivatives 3d–3e [19, 26] (75–88%). The acyl 
oleanolic acid compounds (3a–3e, 1 equiv) were then first 
treated with oxalyl chloride (18 equiv) to give the corre-
sponding acyl chloride, which was then treated with uracil 
(3 equiv) in the presence of Et3N to generate the corre-
sponding acyl oleanolic acid-uracil conjugates (4a–4e, 
Scheme 2) in 11–60% yields. The structures of compounds 
4a–4e were confirmed by NMR and mass spectra.
Cytotoxicity
As anti-tumor effects are the most classical activities of 
oleanolic acid and its derivatives [1, 27–29], these conju-
gates have been evaluated by MTT assay [30, 31] against 
5 adherent tumor cell lines (Hep-G2, A549, BGC-823, 
MCF-7 and PC-3) with 1 as the positive control. 5-Fluo-
rouracil (5-FU), a medication used in the clinical treat-
ment of cancer, is also a pyrimidine analog and was used 
as a positive control in this study. The results are pre-
sented in Table 1.
The results showed that these compounds exhibited 
excellent antiproliferative activities against the tested 
cells, with the IC50 values mainly under 10.0 μM, except 
for compounds 4a and 4b which showed no inhibition 
against the PC-3 cell line. In the Hep-G2, A549, BGC-
823 and MCF-7 cell line assays, all the synthesized com-
pounds displayed much better inhibition than that of 1 
and 5-FU. With a propionyloxy group at C-3, compound 
4b possessed the best inhibition activity against the 
Hep-G2 cell line, almost 5.5-fold and 20-fold stronger 
than 1 and 5-FU, respectively. With a dodecanoyloxy 
group at C-3, compound 4d showed the best inhibition 
activity against the A549 cell line, almost 60-fold and 
84-fold stronger than 1 and 5-FU, respectively. Mean-
while, compound 4a, with an acetoxy group at C-3, 
exhibited the best inhibition activity against the MCF-7 
cell line, more than 126-fold and 215-fold more effective 
than 1 and 5-FU respectively. Compounds 4a (acetoxy), 
4b (propionyloxy) and 4e (palmitoxy) exhibited excellent 
antiproliferative activities against the BGC-823 cell line 
(IC50 < 0.1 μM). Although compounds 4a (acetoxy) and 
4b (propionyloxy) possessed good antiproliferative activi-
ties against the Hep-G2, A549, BGC-823 and MCF-7 
cell lines, they showed no inhibition against the PC-3 
cell line. In the PC-3 assay, the butyryloxy compound 4c 
exhibited the best antiproliferative activity, being 260-
fold and 44-fold stronger than 1 and 5-FU, respectively. 
The results above reveal that in general, the acyl groups 
at the C-3 position of these uracil conjugates have pri-
marily made a great contribution to the antiproliferative 
activities against the tested cell lines.
For further analysis, conjugate 4c was selected to deter-
mine its cytotoxicity selectivity and mechanism of growth 
inhibition on an adherent Hep-G2 cell line. The controls 
of the figures were reused from our previous work [32].
Cytotoxicity selectivity
As shown in Fig.  2, though the inhibition rate of 4c 
against human liver cell line HL-7702 (L-O2) at the 
Scheme 1 Synthesis of acyl oleanolic acid derivatives. Reagents and conditions: (i) anhydride, DMAP, anhydrous CH2Cl2/pyridine, rt (64–89%); (ii) 
acyl chloride, Et3N, anhydrous THF, rt (75–88%)
Scheme 2 Synthesis of oleanolic acid‑uracil conjugates, where n is the number of methylene groups in the acyl group
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concentration of 50 μM was equivalent to that of human 
hepatoma cell line Hep-G2, its inhibition rate against the 
HL-7702 cell line was only approximately 15% at the con-
centration of 10 μM, while the inhibition rate against the 
Hep-G2 cell line was up to 90% at the same concentra-
tion. Thus, it was exhibited that compound 4c showed 
strong cytotoxicity selectivity to human hepatocellular 
carcinoma cells in  vitro at the therapeutically effective 
concentration.
Fluorescence staining
After sequentially staining with acridine orange (AO)/
ethidium bromide (EB) (Fig.  3) and Hoechst 33258 
(Fig.  4), the living cells were treated with compound 4c 
(2.5 and 5.0  μM, 24  h). As depicted in Fig.  3, the living 
cells excluded EB and staining by AO caused a green 
color (Fig. 3a), whereas the Hep-G2 cells treated with 4c 
had obviously changed (Fig.  3b, c). Under fluorescence 
microscopy, early apoptosis cells were observed to emit 
orange or dark orange fluorescence, with nuclear mor-
phological changes, which suggested that 4c could 
induce apoptosis in Hep-G2 cells. This is consistent with 
the results of Hoechst 33258 staining shown in Fig.  4. 
The nuclei of the Hep-G2 cells retained the regular 
round contours in the control group (Fig.  4a), and cells 
with smaller nuclei and condensed chromatin were rarely 
observed. It was found that the contours of some of the 
Hep-G2 cells became irregular even when they were 
exposed to 4c at lower concentration of 2.5 μM, accom-
panied with the nuclei being condensed (as the bright 
blue fluorescence indicates) and the apoptotic bodies 
appeared (Fig. 4b). When treated with 4c at a higher con-
centration of 5.0 μM, the nuclei of many more cells were 
highly condensed and the apoptotic bodies were perva-
sive in the visual field (Fig. 4c). These clear changes to the 
cell morphology suggested the significant cell apoptosis 
induction of 4c on Hep-G2 cells.
Cell cycle analysis
To confirm whether the decrease of cell viability was 
caused by cell cycle arrest, the Hep-G2 cells were treated 
with compound 4c for 48  h at different concentrations 
and then the cell cycle distribution was determined by a 
flow cytometry assay after propidium iodide (PI) staining 
(Fig. 5). The results indicate that conjugate 4c enhanced 
the cell cycle arrest at the G1 phase at different concen-
trations, resulting in a concomitant population increase 
in the G1 phase (60.65–86.49, 87.66 and 73.54%), and 
declines in the cell population in the G2/M (13.83–2.09, 
1.40 and 3.05%) and S-phases (25.52–11.42, 10.95 and 
23.41%).
AnnexinV/propidium iodide assay
To determine whether the observed cell death induced by 
conjugate 4c was due to apoptosis or necrosis, the inter-
actions of Hep-G2 cells with 4c were further investigated 
Table 1 Evaluation of 4a–4e against different tumor cell lines
a IC50 values are presented as the mean ± SD (standard deviation) from three separated experiments
b No inhibition detected
Compounds IC50 (μM)
a
Hep-G2 A549 BGC-823 MCF-7 PC-3
4a 7.83 ± 0.69 4.01 ± 0.37 <0.1 <0.1 NIb
4b 2.81 ± 0.22 15.5 ± 1.34 <0.1 6.53 ± 0.35 NI
4c 5.24 ± 0.05 3.01 ± 0.28 0.22 ± 0.02 6.99 ± 0.57 0.28 ± 0.05
4d 8.49 ± 0.68 0.27 ± 0.03 0.11 ± 0.01 3.51 ± 0.22 10.61 ± 1.13
4e 4.19 ± 0.35 8.76 ± 0.07 < 0.1 5.26 ± 0.41 2.51 ± 0.05
1 15.90 ± 1.13 16.29 ± 1.36 23.74 ± 1.53 12.60 ± 1.09 72.74 ± 6.88
5-FU 55.74 ± 5.09 22.62 ± 2.19 8.82 ± 0.78 21.47 ± 1.99 12.23 ± 1.18
Fig. 2 Cytotoxicity of 4c against Hep‑G2 tumor cells and 
HL‑7702 human liver cells. Hep‑G2 and HL‑7702 cells were cultured 
in medium in the presence of the indicated concentrations of 4c for 
72 h
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using an Annexin V-FITC/PI assay (Fig. 6). The apoptosis 
ratios (including the early and late apoptosis ratios) of 4c 
measured at different concentration points were found 
to be 16.31% (2.5 μM) and 26.43% (5.0 μM), respectively, 
while that of the control was 4.06%. This revealed that 4c 
could mainly induce later period apoptosis in Hep-G2 
cells.
Mitochondrial membrane potential detection
As the mitochondrial membrane potential (Δψ) has been 
considered a new antitumor target [33, 34], the changes 
in Δψ in Hep-G2 cells (treated with conjugate 4c) stained 
with Rhodamine 123 indicated by flow-cytometric 
analysis were tested (Fig. 7). The results indicated that 4c 
induced a marked concentration-dependent decrease of 
Rhodamine 123 fluorescence (decreasing from 86.2% to 
85.8, 81.3 and 65.7% with the increase concentration of 
4c). This indicated that compound 4c can induce mito-
chondrial membrane potential disruption in Hep-G2 
cells.
Caspase-3/9 activity assay
FITC-DEVD-FMK (for caspase-3) and FITC-LEHD-
FMK (for caspase-9) probe assays were carried out to 
determine the death signaling in the caspase family after 
treatment with 4c (5.0  μM, 24  h) in Hep-G2 cells. The 
Fig. 3 Cell morphological observation for cell apoptosis induction on the Hep‑G2 cells treated by 4c. a Control cells; b, c cells treated by 4c for 
24 h; cells were stained by AO/EB, and selected visual fields illustrating the corresponding live cells, early apoptotic cells (white arrow) are shown 
(magnification ×200)
Fig. 4 Cell morphological observation for cell apoptosis induction on the Hep‑G2 cells treated by conjugate 4c. a Control cells; b, c cells treated by 
4c for 24 h; cells were stained by Hoechst 33258, and selected visual fields illustrating the condensed chromatin (white arrow) as occurrence of cell 
apoptosis are shown (magnification ×200)
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proportion of activated-caspase-3 cells after 4c treatment 
was enhanced to 22.7% (Fig. 8a), while that of activated-
caspase-9 cells was enhanced to 22.9% (Fig.  8b). These 
results indicate that 4c could induce cell apoptosis by 
triggering caspase-3/9 activity in Hep-G2 cells.
Conclusions
Five acyl oleanolic acid-uracil conjugates were syn-
thesized and their anti-tumor activities were 
evaluated. These conjugates exhibited excellent antipro-
liferative activities against the tested cells (Hep-G2, A549, 
Fig. 5 Cell cycle progress detection by flow cytometry assay after PI staining of Hep‑G2 cells following treatment with compound 4c: a control 
cells; b, c, d cells treated by 4c for 48 h; e corresponding histograms. *P < 0.05 and **P < 0.01 compared with the control
Fig. 6 Apoptosis ratio detection by Annexin V/PI assay on the Hep‑G2 cells treated by conjugate 4c: a control cells; b, c cells treated by 4c for 24 h
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BGC-823, MCF-7 and PC-3) except compounds 4a and 
4b, which showed no inhibition against the PC-3 cell line. 
Most of the IC50 values were under 10.0 μM, with some 
of them even under 0.1 μM.
Conjugate 4c was selected for further analysis includ-
ing for its cytotoxicity selectivity and its mechanism of 
growth inhibition on the Hep-G2 cell line. The inhibition 
rate of 4c against the HL-7702 cell line was only approxi-
mately 15% (90% against Hep-G2) at the concentration of 
10 μM, indicating that it had strong cytotoxicity selectiv-
ity to human hepatocellular carcinoma cells in vitro. The 
treatment of Hep-G2 cells with this compound, could 
induce changes in the permeability of the mitochondrial 
membrane, and thus cause a decline in the mitochon-
drial membrane potential. With the disruption of the 
mitochondrial membrane potential, changes in cellular 
morphology appeared as a result of significant apop-
tosis induction. Then, cell proliferation in the G1 phase 
was arrested and apoptotic signaling activated caspase-9. 
Caspase-9, as a protease, can activate the apoptotic 
effector caspase-3, eventually causing nuclear apopto-
sis. Further studies of the specific mechanisms of these 
compounds in human malignant tumors are currently 
underway.
Fig. 7 Collapse of mitochondrial membrane potential in the Hep‑G2 cells treated by conjugate 4c. a Control cells; b, c, d cells treated by 4c for 
24 h; cells were stained with Rhodamine 123 for 30 min. The results are expressed as relative fluorescent intensity
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Methods
General
All commercially available solvents and reagents used were 
of analytical grade and were used without further purifica-
tion. All commercial reagents were purchased from Alad-
din (Shanghai) Industrial Corporation. Melting points 
were measured on a RY-1 melting point apparatus. 1H 
and 13C-NMR spectra were recorded on Bruker AV-500 
(500/125 MHz for 1H/13C) spectrometers. Chemical shifts 
are reported as values relative to an internal tetramethyl-
silane standard. The low-resolution mass spectra were 
obtained on a Bruker Esquire HCT spectrometer, and 
HRMS were recorded on a Thermo Scientific Accela—
Exactive High Resolution Accurate Mass spectrometer.
Chemistry
General procedures for synthesis of oleanolic acid‑uracil 
conjugates 4a–4e
To a solution of different acyl oleanolic acid compound 
(3a–3e, 0.2 mmol) in anhydrous CH2Cl2 (3 mL) at 0 °C, 
oxalyl chloride (0.34  mL, 3.6  mmol) was added. After 
stirring at room temperature for 12  h, the mixture was 
evaporated, and co-evaporated with CH2Cl2 (3 × 1 mL). 
The residue was dissolved in dry THF (3 mL), and then 
Et3N (1  mL, 0.7  mmol) and uracil (0.067  g, 0.6  mmol) 
were added at 0  °C. After stirring at r.t. for 24  h, the 
solvent was evaporated. The residue was then taken up 
in H2O (35 mL) and extracted with CH2Cl2 (3 × 20 mL). 
The combined organic layers were washed with H2O and 
brine, dried with MgSO4, filtered and concentrated to 
give a crude product. The crude product was purified by 
flash column chromatography to afford the correspond-
ing product (4a–4e) respectively (Additional file 1).
Compound 4a
Compound 4a was prepared from 3a [15, 19, 20] (1.000 g, 
2.00 mmol) and uracil (0.673 g, 6.00 mmol) according to 
the general procedure. The residue was purified by flash 
column chromatography (Petroleum ether:EtOAc  =  4: 
1). Yield: 0.349  g, 29%, white solid, mp 209–211  °C. 1H 
NMR (500 MHz, CDCl3) δ 0.69, 0.85, 0.86, 0.99 and 1.17 
(5 s, each 3H, 5 × CH3), 0.92 (s, 6H, 2 × CH3), 0.63–2.15 
(m, 22H), 2.05 (s, 3H, CH3COO), 2.99 (dd, 1H, J =  3.2, 
13.2 Hz, H-18), 4.48 (dd, 1H, J = 6.6, 9.3 Hz, H-3), 5.28 
(t, 1H, J = 3.2 Hz, H-12), 5.74 (d, 1H, J = 8.3 Hz, H-5Ura), 
7.51 (d, 1H, J = 8.3 Hz, H-6Ura), 8.20 (brs, 1H, NH). 13C 
NMR (125  MHz, CDCl3) δ 15.6, 16.8, 18.2, 18.3, 21.4, 
23.0, 23.7, 24.0, 26.1, 27.7, 28.2, 30.0, 30.7, 32.7, 33.2, 
33.9, 37.0, 37.9, 38.4, 39.8, 42.0, 43.2, 46.5, 47.5, 53.3, 
55.3, 81.0, 103.0, 123.6, 141.7, 143.3, 148.8, 162.7, 171.2, 
182.0. HRMS (ESI) m/z: [M−H]+ calcd for C36H51N2O5, 
591.3798; found 591.3808.
Fig. 8 Activation of caspase‑3/9 by conjugate 4c in Hep‑G2 cells after treatment with 5.0 μM for 24 h: a activation of caspase‑3; b activation of 
caspase‑9
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Compound 4b
Compound 4b was prepared from 3b [19, 25] (0.300  g, 
0.59  mmol) and uracil (0.196  g, 1.75  mmol) accord-
ing to the general procedure. The residue was puri-
fied by flash column chromatography (Petroleum 
ether:EtOAc = 5: 1). Yield: 0.213 g, 60%, white solid, mp 
119–121  °C. 1H NMR (500  MHz, CDCl3) δ 0.69, 0.84, 
0.85, 0.98 and 1.17 (5 s, each 3H, 5 × CH3), 0.92 (s, 6H, 
2 × CH3), 1.14 (t, J = 7.6 Hz, CH3), 0.63–2.13 (m, 22H), 
2.32 (q, 2H, J = 7.3 Hz, CH2COO), 2.99 (dd, 1H, J = 2.5, 
12.8 Hz, H-18), 4.48 (dd, 1H, J = 6.5, 9.3 Hz, H-3), 5.28 
(s, 1H, H-12), 5.74 (d, 1H, J =  8.3  Hz, H-5Ura), 7.50 (d, 
1H, J  =  8.3  Hz, H-6Ura), 8.97 (brs, 1H, NH). 13C NMR 
(125  MHz, CDCl3) δ 9.4, 15.6, 16.9, 18.1, 18.2, 22.9, 
23.6, 24.0, 26.1, 27.7, 28.1, 28.2, 30.0, 30.6, 32.7, 33.1, 
33.9, 37.0, 37.9, 38.4, 39.8, 42.0, 43.2, 46.5, 47.5, 53.2, 
55.3, 80.6, 103.0, 123.6, 141.7, 143.3, 149.0, 163.4, 174.4, 
182.0. HRMS (FTMS  +  pESI) m/z: [M−H]+ calcd for 
C37H53N2O5, 605.3955; found 605.3979.
Compound 4c
Compound 4c was prepared from 3c [19, 25] (0.200  g, 
0.38 mmol) and uracil (0.127 g, 1.14 mmol) according to 
the general procedure. The residue was purified by flash 
column chromatography (Petroleum ether:EtOAc = 3: 1). 
Yield: 0.131 g, 56%, white solid, mp 285–287 °C. 1H NMR 
(500 MHz, CDCl3) δ 0.69, 0.85, 0.86, 0.95, 0.99 and 1.18 
(6 s, each 3H, 6 × CH3), 0.92 (s, 6H, 2 × CH3), 0.63–2.15 
(m, 24H), 2.28 (t, 2H, J = 7.1 Hz, CH2COO), 2.99 (dd, 1H, 
J =  3.3, 13.2  Hz, H-18), 4.49 (dd, J =  5.7, 10.1  Hz, 1H, 
H-3), 5.28 (s, 1H, H-12), 5.74 (d, 1H, J = 8.3 Hz, H-5Ura), 
7.50 (d, 1H, J = 8.3 Hz, H-6Ura), 8.30 (brs, 1H, NH). 13C 
NMR (100 MHz, CDCl3) 13.7, 15.4, 16.8, 17.2, 18.2, 18.6, 
23.4, 23.6, 25.7, 25.8, 27.8, 28.0, 30.7, 32.0, 32.7, 33.0, 33.8, 
36.8, 36.9, 37.7, 38.1, 40.0, 41.3, 41.9, 45.8, 47.4, 47.5, 
55.3, 80.5, 104.5, 112.3, 123.0, 139.6, 142.9, 149.0, 161.8, 
173.5, 175.2. APCI-MS m/z: 619.4 [M−H]+. HRMS (ESI) 
m/z: [M−H]+ calcd for C38H55N2O5, 619.4111; found 
619.4113.
Compound 4d
Compound 4d was prepared from 3d [19] (0.280  g, 
0.44 mmol) and uracil (0.148 g, 1.32 mmol) according to 
the general procedure. The residue was purified by flash 
column chromatography (Petroleum ether:EtOAc  =  5: 
1). Yield: 0.072 g, 22%, white solid. 1H NMR (500 MHz, 
CDCl3) δ 0.70, 1.00 and 1.19 (3 s, each 3H, 3 × CH3), 0.87 
and 0.93 (2 s, each 6H, 4× CH3), 0.63–2.10 (m, 43H), 2.30 
(s, 2H, CH2COO), 3.01 (d, 1H, J = 11.8 Hz, H-18), 4.50 
(s, 1H, H-3), 5.30 (s, 1H, H-12), 5.74 (d, 1H, J = 7.5 Hz, 
H-5Ura), 7.52 (d, 1H, J =  7.7  Hz, H-6Ura), 8.72 (brs, 1H, 
NH). 13C NMR (125 MHz, CDCl3) δ 14.3, 15.6, 16.9, 18.1, 
18.2, 22.8, 23.0, 23.6, 24.0, 25.3, 26.1, 27.7, 28.2, 29.3, 
29.4, 29.5, 29.6, 29.7, 30.0, 30.7, 32.1, 32.6, 33.2, 33.9, 
35.0, 37.0, 37.9, 38.4, 39.8, 42.0, 43.2, 46.5, 47.5, 53.2, 
55.3, 80.5. 103.0, 123.6, 141.7, 143.3, 148.9, 163.1, 173.9, 
182.0. HRMS (ESI) m/z: [M−H]+ calcd for C46H71N2O5, 
731.5363; found 731.5387.
Compound 4e
Compound 4e was prepared from 3e [26] (0.347  g, 
0.50 mmol) and uracil (0.168 g, 1.50 mmol) according to 
the general procedure. The residue was purified by flash 
column chromatography (Petroleum ether:EtOAc  =  5: 
1). Yield: 0.044  g, 11%, white solid, mp 89–91  °C. 1H 
NMR (500 MHz, CDCl3) δ 0.69, 0.85, 0.86, 0.99 and 1.18 
(5 s, each 3H, 5× CH3), 0.92 (s, 6H, 2× CH3), 0.63–2.10 
(m, 51H), 2.29 (t, 2H, J = 7.5 Hz, CH2COO), 2.99 (dd, 1H, 
J = 2.7, 12.9 Hz, H-18), 4.48 (dd, 1H, J = 5.9, 9.8 Hz, H-3), 
5.28 (s, 1H, H-12), 5.74 (d, 1H, J = 8.3 Hz, H-5Ura), 7.50 
(d, 1H, J = 8.3 Hz, H-6Ura), 8.17 (brs, 1H, NH). APCI-MS 
m/z: 787.7 [M−H]+. HRMS (ESI) m/z: [M−H]+ calcd for 
C50H79N2O5, 787.5989; found 787.6003.
Cell lines and culture
The human hepatocellular cell line Hep-G2, human 
lung cancer cell line A549, human gastric tumor cell line 
BGC-823, human breast tumor cell line MCF-7, human 
prostate cancer cell line PC-3 and human hepatocyte cell 
line HL-7702, these adherent cells were purchased from 
the Cell Bank of Type Culture Collection of the Chinese 
Academy of Sciences (Shanghai) and cultured in DMEM 
medium supplemented with 10% FCS (Fetal Calf Serum). 
The cells were incubated in an atmosphere of 5% CO2 
and 95% air at 37 °C.
MTT assay
The MTT assay was carried out according to a descrip-
tion in a published study [30, 31]. Cells were seeded in 
96-well plates and incubated in a CO2 incubator at 37 °C. 
The tested compounds were dissolved in fresh culture 
medium with 2% DMSO to afford various concentrations 
(100, 50, 10, 5, 1 or 0.1 μmol/L). When the cells adhered, 
compounds at different concentrations were added to 
every well. The control wells contained medium supple-
mented with 2% DMSO. After incubation for another 
72 h, 20 μL MTT (5%) was added to each well, and the 
cells were incubated for an additional 4 h at 37 °C. At last, 
the medium was removed carefully and dimethyl sulfox-
ide (100 μL) was added to each well. Then the plate was 
kept on a shaker for 10 min to mix these solutions prop-
erly. The absorbance of each well was scanned with an 
electrophotometer at 570 nm. Each concentration treat-
ment was performed in triplicate wells. The IC50 values 
were estimated by fitting the inhibition data to a dose-
dependent curve using a logistic derivative equation.
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AO/EB staining
This assay was carried out according to a description in 
a published study [35]. Cells were seeded at a concentra-
tion of 5 ×  104 cell/mL in a volume of 2  mL on a ster-
ile cover slip in six-well tissue culture plates. Following 
incubation, the RPMI 1640 medium was removed and 
replaced with fresh medium plus 10% FCS and supple-
mented with compound 4c at the indicated concentra-
tion. After the treatment period (24  h), the cover slip 
with monolayer cells was inverted on a glass slide with 
20 μL of AO/EB stain (100 mg/mL). The fluorescence was 
read on a Nikon ECLIPSETE2000-S fluorescence micro-
scope (Japan).
Hoechst 33258 staining
This assay was carried out according to a description in a 
published study [35]. Cells grown on a sterile cover slip in 
six-well tissue culture plates were treated with compound 
for a certain range of time. The culture medium contain-
ing compounds was removed, and the cells were fixed 
in 4% paraformaldehyde for 10 min. After being washed 
twice with PBS, the cells were stained with 0.5  mL of 
Hoechst 33258 (0.5  μg/mL, Beyotime) for 5  min and 
then again washed twice with PBS. The stained nuclei 
were observed under a Nikon ECLIPSETE2000-S fluores-
cence microscope using 350  nm excitation and 460  nm 
emission.
Mitochondrial membrane potential measurement
This assay was carried out as described in a published 
study [34]. The depolarization of the mitochondrial 
membrane potential for cell apoptosis results in the loss 
of Rhodamine123 from the mitochondria and a decrease 
in the intracellular fluorescence intensity. Prepared Hep-
G2 cells were harvested and washed twice in cold PBS 
and then resuspended in Rhodamine 123 (2  μM) for 
30  min in the dark. The fluorescence was measured by 
flow cytometry with an excitation wavelength of 485 nm 
and emission wavelength of 530 nm.
Flow cytometric analysis of cell cycle and apoptosis
This assay was carried out according to a description in a 
published study [35]. The induced apoptosis was assayed 
by the Annexin V-FITC Apoptosis Detection kit (Beyo-
time, China), according to the manufacturer’s instruc-
tions. Briefly, the prepared Hep-G2 cells (1 ×  106 cells/
mL) were washed twice with ice-cold PBS and then 
resuspended gently in 500 μL of binding buffer. Thereaf-
ter, the cells were stained in 5 μL of Annexin V-FITC and 
shaken well. Finally, the cells were mixed with 5 μL of PI, 
incubated for 20 min in the dark and subsequently ana-
lyzed using an FACS AriaII (Becton–Dickinson).
Determination of caspase-3 and caspase-9 activities 
by flow cytometric analysis
According to a description in a published study [35], the 
measurement of the caspase-3 and caspase-9 activities 
was performed by a CaspGLOW™ Fluorescein Active 
Caspase-3 and Caspase-9 Staining Kit. The prepared 
Hep-G2 cells were harvested at a density of 1 × 106 cells/
mL in RPMI 1640 medium supplemented with 10% FCS. 
A total of 300 μL each from the induced and control cul-
tures were incubated with 1  μL of FITC-DEVD-FMK 
(caspase-3) or FITC-LEHD-FMK (caspase-9) for 1 h in a 
37  °C incubator with 5% CO2. Flow cytometric analysis 
was performed using a FACS AriaII flow cytometer (Bec-
ton–Dickinson) equipped with a 488 nm argon laser.
Statistical analysis
The experiments were repeated three times, and the 
results were presented as mean  ±  standard deviation 
(SD). Student’s t test was used to process the statistical 
significance and the differences between groups with 
P < 0.05 were considered significant.
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